Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT02845323 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma
Bladder Cancer

Interventions

DRUG: Nivolumab in combination with Urelumab
DRUG: Nivolumab monotherapy

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]